VaxInnate Corporation was awarded a grant to fund the development of a recombinant vaccine for the prevention of dengue by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Dengue is a mosquito-borne disease that kills an estimated 25,000 people annually. The grant provides funding of $2.2 million over a period of three years to develop a recombinant tetravalent dengue vaccine using VaxInnate’s proprietary technology. The technology involves “genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system, which dramatically improves the potency, manufacturing capacity and cost-effectiveness of vaccines.”

Full media release of April 04, 2013: http://www.businesswire.com/news/home/20130404005347/en/VaxInnate-Awarded-U.S.-Government-Grant-Develop-Dengue